Get the Stockscreener App
5.06
3.48%
0.17
Molecular Partners Ag Adr stock is traded at $5.06, with a volume of 3,614.
It is up +3.48% in the last 24 hours and down -7.33% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$4.89
Open:
$5.12
24h Volume:
3,614
Relative Volume:
0.25
Market Cap:
$183.21M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-2.3631
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
-1.94%
1M Performance:
-7.33%
6M Performance:
-16.36%
1Y Performance:
+7.89%
1-Day Range:
$4.86
$5.12
1-Week Range:
$4.86
$5.15
52-Week Range:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.97 | 183.21M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.04 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.49 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.78 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Here's Why Seagate (STX) is a Strong Momentum Stock - Yahoo Finance
Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M - TipRanks
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Molecular Partners expands 212Pb co-development agreement with Orano Med - TipRanks
Molecular Partners shares gain on Leerink's outperform rating - Investing.com
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
Market Data Center - Barron's
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):